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Background: For single nucleotide polymorphism – SNP
(SNP – Single Nucleotide Polymorphism) is characterized by
phenomenon of allelic imbalance (AI). The phenomenon of allelic
imbalanced (AI) is typical of many genes in different malignan-
cies. Allelic imbalanced may result allelic deletions (loss of one
copy of the locus) or amplification of one allele, resulting in only
a single allelic variant of SNP is determined in the tumor in the
PCR. Phenomenon of AI in tumors of breast cancer (BC) is consid-
ered in one or more genes. The phenomenon of AI during
chemotherapy (CT) and especially in the longer format of the
gene had not previously been studied.
Thus, the aim of this work was to study microarray imbal-
anced allele in mammary tumors during neoadjuvant chemother-
apy (NCT).
Materials and methods: The study included 26 breast cancer
patients with stage IIA – IIIC. The patients in the neoadjuvant
mode received 2–4 courses of chemotherapy regimens FAC or
CAX. DNA from 26 paired samples before treatment and opera-
tional samples were isolated by dialing QIAampDNA miniKit
(Qiagen, Germany). Microarray analysis was performed on DNA
chips of high density company Affymetrix (USA) CytoScanTM
HD Array, which contains more than 750 thousand SNP. Microar-
ray analysis was performed on SNP genotypes DNA tumor tissue
before and after treatment for each patient and recorded as
change occurring allelic imbalanced tumor tissue genotype
(AA > AB > AB AA BB > AB > AB BB) during therapy.
Results: The frequency of the AI in breast tumor during NCT
was highly variable (within 0.9–66.5%) of the studied SNP
(6850 – 497,979 SNP). For each patient, frequency shift genotype
(homozygous in heterozygous genotype, and vice versa) was cal-
culated as a percentage of all the shifts. Changes in the wild or
mutant heterozygous genotypes (AA or BB > AB) were combined
into one group; the second group was the sum of the change in
the heterozygous genotype homozygous wild genotype or the
mutant (AB > AA or BB). We have found that the direction of the
AI was significantly associated effect of NCT. In the group of
patients with partial regression, the direction of AI change from
homozygous to heterozygous genotype often occurs (AA or
BB > AB) (9/14, 64%), whereas patients with no response to the
NCT (with stabilization or progression) have the opposite effect.
All these patients (12/12 cases) have the direction of the change
of AI from heterozygous genotype to homozygous (AA or AB >
BB) (p = 0.00071). AI during chemotherapy at the level of the
marked tendency (Log-rank test, p = 0.062) is associated with
5-year metastasis-free survival. Low metastasis-free survival rate
is observed in patients with AI in the direction of the change from
the heterozygous to homozygous genotype, while 100% survival
is noted in patients with change from homozygous to heterozy-
gous genotypes, and this imbalanced t allele is a favorable prog-
nostic factor.
Conclusion: Allelic imbalanced in breast tumor during NCT
phenomenon is massive and may affect up to 67% of SNP. AI
may occur in the direction of change from homozygous to
heterozygous genotype, and it is associated with a good response
to treatment and 100% metastasis-free survival. Apparently, this
can be explained by the fact that the change from homozygous
genotypes to heterozygous occur due to partial destruction of
tumor cells by chemotherapy, resulting in the increase of stromal
elements. In contrast, AI in the direction change from heterozy-
gous to homozygous genotype during NCT is associated with no
response to chemotherapy due to metastasis and occurring of
new mutant clones in the tumor.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.113
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Dendritic cells (DCs) are the most potent antigen-presenting
cells, which play crucial role in initiation and maintenance of
immune response. However, DCs of high-grade glioma patients
are characterized by some functional impairment including
reduced TNFa-mediated antitumor cytotoxic activity and low
migratory activity. Tumor-produced soluble molecules can pro-
foundly affect the differentiation and maturation of DCs and
influence the functional activity of DCs. The aim of the present
study was to determine the effect of supernatants of primary
glioma cell lines on the migration and the cytotoxic activity of
healthy donor DCs. The study included 11 healthy donors and 7
patients with histologically verified glioma Grade II (2 patients)
and glioma Grade IV (5 patients). DCs were generated from
peripheral blood monocytes of healthy donors in the presence
of GM-CSF and IFN-alpha (IFN-DCs) followed by the addition of
lipopolysaccharide (LPS Escherichia coli). Primary glioma cell cul-
tures from tissue samples of studied patients were obtained by
mechanical and enzymatic (0.3% collagenase IA) disaggregation
followed by culturing in DMEM/F12 medium containing 10%
FCS. 7-day supernatants were collected upon reaching the cellular
subconfluence. Migratory capacity of donor IFN-DCs in response
to supernatants (v/v 25%) of primary glioma cell cultures was
measured in trans-well culture chamber. DCs that migrated to
the bottom chamber with medium alone as a control or with
supernatants were counted by FACS analysis using BD calibration
beads. Cytotoxic activity of donor IFN-DCs against tumor cell line
HEp-2 was studied using MTT-assay for 24 h at a ratio of DC: HEp-
2 1:1. IFN-DCs were preincubated for 2 h with supernatants of
primary glioma cell cultures. Migration index of donor IFN-DCs
to lymphoid chemokine CCL19 (100 ng/ml) was an average of
6.5 ± 2.1. Migration capacity of IFN-DCs towards concentration
gradient of primary glioma culture supernatants was significantly
higher. Supernatants of low-grade glioma cultures as well as of
high-grade glioma cultures effectively induced chemotaxis of
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IFN-DCs. Migration index in response to concentration gradient of
primary glioma line-derived soluble factors (6 cell lines) ranged
from 32.6 ± 9 to 48.4 ± 15.5. To assess the effect of supernatants
of primary lines on the cytotoxic activity of IFN-DCs four primary
high-grade glioma lines were used. The cytotoxicity of intact LPS-
stimulated donor IFN-DCs against HEp-2 cells was an average of
34.8 ± 7.4%. Supernatant pretreating of IFN-DCs reduced the cyto-
toxic activity of DCs in 8 out of 16 experiments (with an average of
43%). In other 8 cases, supernatants of high-grade glioma lines, in
contrast, possessed a mild stimulating activity and enhanced the
cytotoxicity of DCs on average about of 34%. Thus, tumor cells in
glioma patients produce chemoattractants capable of providing
migration of DCs to tumor. At the same time glioma-derived
soluble factors change the cytotoxic activity both ways. One can
suppose thereupon that impairment of DC cytotoxic activity in
glioma patients occurs not only due to tumor cell impact but
because of unknown mechanisms.
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Glioma is the most common type of primary brain tumor.
Despite aggressive therapy, glioma virtually always recurs. Sol-
uble factors produced by glioma cells play an important role in
progression of tumor growth. Glioma-derived soluble factors
can stimulate tumor cell proliferation in autocrine and paracrine
manners, affect the tumor microenvironment and promote
angiogenesis and metastasis. Besides, glioma-derived cytokines
are able to disturb antitumor immune response by inhibiting
the functions of effector lymphocytes and inducing immunosup-
pressive cells. The aim of the present study was to determine the
profile of cytokines produced by primary low-grade and high-
grade glioma cell cultures. The study was held in 21 patients with
brain tumors after receiving a written informed consent. There
were 6 patients with histologically verified low-grade glioma
(Grade II) and 15 patients – with high-grade glioma (Grade III–
IV). Tumor tissues from patients were obtained during surgical
resection. Cell suspensions were prepared by mechanical and
enzymatic disaggregation followed by culturing in DMEM/F12
medium containing 10% FCS. The levels of 27 cytokines were
measured using multiplex analysis (Bio-Rad, USA) in 7-days
supernatants collected upon reaching the cellular subconfluence.
Low-grade glioma cells produced low level (Me <25 pg/ml) of pro-
inflammatory cytokines IL-1b, TNFa and anti-inflammatory
cytokines IL1-ra, IL-10, IL-13. The level of these cytokines in
supernatants of high-grade glioma cultures were in the middle
range (25–500 pg/ml), excepting IL-1b (Me 5.9 pg/ml). Concerning
cytokines with immunoregulatory activity in supernatants of
low-grade glioma cultures, only IL-12 level was in the middle
range (Me 77 pg/ml), whereas the level of other immunoregula-
tory cytokines (IL-2, IFNc, IL-4, IL-5, IL-15, IL-17) was low (Me
<25 pg/ml). High-grade glioma cells actively produced not only
IL-12 (Me 336 pg/ml), but also IFNc and IL-15 (Me 355 pg/ml and
Me 57 pg/ml, respectively). The level of growth factors and cytoki-
nes, which act as regulators of hemo- and immunopoesis, was
low in supernatants of low-grade glioma cultures. Median con-
centration of G-CSF, GM-CSF, IL-7, FGFb and PDGF was less than
25 pg/ml, but IL-9 concentration was in the middle range (Me
74 pg/ml) . High-grade glioma cultures produced, besides IL-9,
also G-GSF (Me 263 pg/ml), FGFb (Me 60 pg/ml) and PDGF (Me
63 pg/ml). The level of FGFb and G-GSF correlated with the glioma
grade (R = 0.87, p = 0.002, and R = 0.66, p = 0.002, respectively). The
IL-7 and GM-CSF level in high-grade culture supernatant was low
(Me <25 pg/ml). IL-6 and VEGF play important role in the mainte-
nance of tumor cell proliferation and the stimulation of tumor
angiogenesis. Both low-grade and high-grade glioma cultures pro-
duced high level (>500 pg/ml) of IL-6 (Me 1933 pg/ml and 3531 pg/ml,
respectively) and VEGF (Me 1004 pg/ml and 14887 pg/ml, respec-
tively). VEGF level correlated with glioma grade (R = 0.86,
p = 0.002). Concerning CC-chemokines the level of Eotaxin was
low in low-grade glioma cultures (Me 11 pg/ml). The mild-level
production was found for MIP-1a (Me 71 pg/ml) and RANTES
(231 pg/ml), high-level – for MCP-1 (Me 9468 pg/ml) and MIP-1b
(Me 990 pg/ml). High-grade glioma cells produced not only MIP-
1a (Me 208 pg/ml) and RANTES (Me 311 pg/ml) in the middle range
but also Eotaxin (Me 107 pg/ml). Eotaxin level correlated with the
glioma grade (R = 0.87, p = 0.002). High-grade glioma cells pro-
duced highlevel of MCP-1 (Me 9868 pg/ml) and MIP-1b (Me
1923 pg/ml). Both low-grade and high-grade glioma cells
produced high level of CXC-chemokines IL-8 and IP-10 (Me
>1000 pg/ml). The level of IL-8, which acts as chemoattractant
for immune cells as well as for endothelial cells involved in angio-
genesis, correlated with glioma grades (R = 0.72, p = 0.002). Thus,
the grade of gliomas associated with broadening the spectrum
of cytokines and enhanced level of cytokines production by tumor
cells.
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Exosomes are small vesicles formed in vesicular bodies in the
endosomal network many different types of cells. Exosomes are
abundantly released by tumor cells. Current knowledge of exo-
somes suggests that they can play an important role in the devel-
opment and progression of cancer through modulation of
intercellular communication within the tumour microenviron-
ment by the transfer of protein, lipid, and RNA cargo.
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